Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of selective COX-II inhibitor in patients with regionally disseminated stomach cancer treated by palliative resection (so called R1 or R2 gastrectomy).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Rofecoxib

Criteria

Inclusion Criteria:

• Stomach cancer with peritoneal or lymphatic spread beyond the scope of curative resection

• Palliative resection can be performed

• Normal RFT

Exclusion Criteria:

• Solid organ metastases

• Poor performance status

• On long-term aspirin or NSAID

• Renal or hepatic dysfunction

• Bleeding disorder

• Hypersensitive to COX-II inhibitors/aspirin/NSAID

• No history of myocardial infarct or stroke